文献速递临床试验与 GCP

高剂量氟伏沙明与COVID-19门诊患者症状持续恢复时间:ACTIV-6随机临床试验

Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01

ACTIV-6平台随机临床试验在美国103个中心纳入1175例≥30岁、确诊SARS-CoV-2感染且至少2个急性COVID-19症状持续≤7天的门诊患者,比较氟伏沙明(首日50 mg每日两次,随后100 mg每日两次共12天)与安慰剂。主要分析纳入589例氟伏沙明组和586例安慰剂组,两组持续恢复时间无差异(调整HR 0.99,95%可信区间0.89-1.09;疗效P=0.40),未报告死亡。结论认为氟伏沙明不缩短轻中度COVID-19门诊患者的症状持续时间。

要点

  • 氟伏沙明100 mg每日两次与安慰剂相比,持续恢复时间无差异(调整HR 0.99,95%可信区间0.89-1.09;疗效P=0.40)。
  • 未调整的中位持续恢复时间在干预组和安慰剂组均为10天(95%CI 10-11)。
  • 未报告死亡;6例参与者发生7起严重不良事件(氟伏沙明组2例,安慰剂组4例)。

核心结论

  • 在轻中度COVID-19门诊患者中,氟伏沙明治疗不缩短COVID-19症状持续时间。

研究设计与样本

  • ACTIV-6平台随机临床试验,旨在评估老药新用于轻中度COVID-19。
  • 2022年8月25日至2023年1月20日在美国103个中心纳入1175例参与者评估氟伏沙明。
  • 参与者为30岁及以上、确诊SARS-CoV-2感染且至少2个急性COVID-19症状持续7天或更短。
  • 随机接受氟伏沙明(第1天50 mg每日两次,随后100 mg每日两次共12天,n=601)或安慰剂(n=607)。
  • 随访至第28天。

主要发现

  • 1208例随机并接受研究药物的参与者中,中位(IQR)年龄50(40-60)岁,65.8%为女性,45.5%为西班牙裔/拉丁裔,76.8%报告接受至少2剂SARS-CoV-2疫苗。
  • 主要分析纳入589例氟伏沙明组和586例安慰剂组,持续恢复时间无差异(调整HR 0.99,95%可信区间0.89-1.09;疗效P=0.40)。
  • 未调整的中位持续恢复时间在干预组和安慰剂组均为10天(95%CI 10-11)。
  • 未报告死亡;35例参与者报告医疗使用事件(预设为死亡、住院或急诊/紧急护理就诊):氟伏沙明组14例 vs 安慰剂组21例(HR 0.69,95%可信区间0.27-1.21;疗效P=0.86)。
  • 6例参与者发生7起严重不良事件(氟伏沙明组2例,安慰剂组4例),无死亡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The effect of higher-dose fluvoxamine in reducing symptom duration among outpatients with mild to moderate COVID-19 remains uncertain. OBJECTIVE: To assess the effectiveness of fluvoxamine, 100 mg twice daily, compared with placebo, for treating mild to moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: The ACTIV-6 platform randomized clinical trial aims to evaluate repurposed medications for mild to moderate COVID-19. Between August 25, 2022, and January 20, 2023, a total of 1175 participants were enrolled at 103 US sites for evaluating fluvoxamine; participants were 30 years or older with confirmed SARS-CoV-2 infection and at least 2 acute COVID-19 symptoms for 7 days or less. INTERVENTIONS: Participants were randomized to receive fluvoxamine, 50 mg twice daily on day 1 followed by 100 mg twice daily for 12 additional days (n = 601), or placebo (n = 607). MAIN OUTCOMES AND MEASURES: The primary outcome was time to sustained recovery (defined as at least 3 consecutive days without symptoms). Secondary outcomes included time to death; time to hospitalization or death; a composite of hospitalization, urgent care visit, emergency department visit, or death; COVID-19 clinical progression scale score; and difference in mean time unwell. Follow-up occurred through day 28. RESULTS: Among 1208 participants who were randomized and received the study drug, the median (IQR) age was 50 (40-60) years, 65.8% were women, 45.5% identified as Hispanic/Latino, and 76.8% reported receiving at least 2 doses of a SARS-CoV-2 vaccine. Among 589 participants who received fluvoxamine and 586 who received placebo included in the primary analysis, differences in time to sustained recovery were not observed (adjusted hazard ratio [HR], 0.99 [95% credible interval, 0.89-1.09]; P for efficacy = .40]). Additionally, unadjusted median time to sustained recovery was 10 (95% CI, 10-11) days in both the intervention and placebo groups. No deaths were reported. Thirty-five participants reported health care use events (a priori defined as death, hospitalization, or emergency department/urgent care visit): 14 in the fluvoxamine group compared with 21 in the placebo group (HR, 0.69 [95% credible interval, 0.27-1.21]; P for efficacy = .86) There were 7 serious adverse events in 6 participants (2 with fluvoxamine and 4 with placebo) but no deaths. CONCLUSIONS AND RELEVANCE: Among outpatients with mild to moderate COVID-19, treatment with fluvoxamine does not reduce duration of COVID-19 symptoms. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04885530.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Stewart TG, Rebolledo PA, Mourad A, et al. Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial. JAMA. 2023. PMID: 37976072. doi:10.1001/jama.2023.23363

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。